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Translating experimental findings into clinically effective therapies is one of the major bottlenecks
of modern medicine. As this has been particularly true for cerebrovascular research, attention has
turned to the quality and validity of experimental cerebrovascular studies. We set out to assess the
study design, statistical analyses, and reporting of cerebrovascular research. We assessed
all original articles published in the Journal of Cerebral Blood Flow and Metabolism during the
year 2008 against a checklist designed to capture the key attributes relating to study design,
statistical analyses, and reporting. A total of 156 original publications were included (animal, in vitro,
human). Few studies reported a primary research hypothesis, statement of purpose, or measures to
safeguard internal validity (such as randomization, blinding, exclusion or inclusion criteria). Many
studies lacked sufficient information regarding methods and results to form a reasonable judgment
about their validity. In nearly 20% of studies, statistical tests were either not appropriate or
information to allow assessment of appropriateness was lacking. This study identifies a number of
factors that should be addressed if the quality of research in basic and translational biomedicine is
to be improved. We support the widespread implementation of the ARRIVE (Animal Research
Reporting In Vivo Experiments) statement for the reporting of experimental studies in biomedicine,
for improving training in proper study design and analysis, and that reviewers and editors adopt a
more constructively critical approach in the assessment of manuscripts for publication.
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Introduction
Translating experimental findings into clinically
effective therapies is one of the major bottlenecks
of modern medicine. That is, bench findings rarely
lead to bedside treatments. This ‘translational road-
block’ is particularly evident in the cerebrovascular
research field, in which despite numerous promising
preclinical trials, only few treatments of proven
efficacy are available (Dirnagl, 2006; O’Collins et al,
2006; Macleod et al, 2009). As little has been known
about the quality of preclinical studies (Dirnagl,
2006; O’Collins et al, 2009), some have suggested
that low study quality at various stages in the
research process might have reduced the internal
validity of experimental studies (Dirnagl, 2006;
Zinsmeister and Connor, 2008).
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www.jcbfm.comAn extensive literature has accumulated with a
primary focus of quality assessment of clinical trials,
specifically assessing study design, statistical analy-
sis, and trial reporting (Altman, 1998, 2002; Sarter
and Fritschy, 2008; Glantz, 1980). This paved the
way for establishment of standards for conducting
and reporting clinical trials—namely the initia-
lization and implementation of practices such as
Cochrane (http://www.cochrane.org), CONsolidated
Standards of Reporting Trials (CONSORT) (http://
www.consort-statement.org), web-based trial data-
bases (e.g., http://www.clinicaltrials.gov, http://www.
controlled-trials.com), and STrengthening the Reporting
of OBservational studies in Epidemiology (STROBE)
(http://www.strobe-statement.org) (Bellolio et al,
2008; Moher et al, 2001a,b). These measures have
vastly improved the validity of clinical trials and
ultimately their impact on patients (Moher et al,
2001a). However, in the translational preclinical
realm, and particularly in translational cerebrovas-
cular medicine, such approaches have been advo-
cated more recently, e.g., Stroke Academia Industry
Roundtable (STAIR) (http://www.thestair.org) and
Collaborative Approach to Meta Analysis and
Review of Animal Data from Experimental Stroke
(CAMARADES) (http://www.camarades.info) (Dir-
nagl, 2006; Macleod et al, 2009).
Despite the lessons learned through clinical trial
quality assessment, few studies have formally
investigated such factors in the basic science and
translational preclinical trial realms (Dirnagl, 2006).
Those that have, included publications from more
than one scientific journal and assessed publications
across various research fields (Kilkenny et al, 2009;
Ioannidis, 2005; Nieminen et al, 2006; Schroter et al,
2008). To our knowledge, no systematic investigation
focusing on study design, statistical analysis, and
reporting in the field of translational cerebrovascular
research has been carried out.
The purpose of this study was to assess the status
quo of scientific reporting, experimental design, and
statistical analysis in the field of experimental
cerebrovascular medicine. In a first attempt, we
focused on the Journal of Cerebral Blood Flow and
Metabolism (JCBFM), one of the leading journals in
the field of experimental cerebrovascular research.
We chose JCBFM, the official journal of the
International Society for Cerebral Blood Flow and
Metabolism, as it stands at the interface between
basic and clinical neurovascular research. It features
timely and relevant high-quality research while
highlighting experimental, theoretical, and clinical
aspects of brain circulation, metabolism, and ima-
ging (http://www.nature.com/jcbfm). According to
the 2009 Journal Citation Report, the journal has an
impact factor of 5.457, and ranks 29th of 230 journals
in neuroscience, 14th of 105 journals in endocrinol-
ogy and metabolism, and 10th out of 61 in hematol-
ogy (Thomson Reuters, 2010). As an internationally
esteemed source of information in translational
cerebrovascular medicine, JCBFM is well suited to
survey reporting and quality aspects in this field; our
prediction was that, because JCBFM ratings are high
and it is a leading journal in the field, the quality
of experimental studies (based on design, statistics,
and reporting) would also be very high.
Methods
Publication Searches
To assess the quality of research reporting, experi-
mental design, and statistical analysis in all original
articles published in JCBFM from January 2008 through
December 2008, a full version of JCBFM volume 28
(numbers 1 to 12) was secured in both electronic and hard
copy format. A nonblinded reviewer (HV) then system-
atically identified original scientific publications within
JCBFM volume 28.
Original publications were categorized according to
study type: animal (including rodents, primates, canines,
and birds), in vitro, or human studies, review articles,
commentaries, communications, errata, and corrigenda.
Inclusion and Exclusion Criteria for Quality
Assessment
All original articles published in JCBFM volume 28 were
eligible for inclusion. Review articles (8), commentaries or
communications (21), or errata and corrigenda (8) were
excluded.
Publication Quality Assessment
Questionnaire: We developed a checklist questionnaire to
capture the key aspects of the reporting of (1) experimental
design, (2) experimental analysis and statistics, and (3) the
overall quality of reporting. Such checklists for reporting
standards are commonly used in other research domains
(particularly in clinical trials), and we began by creating a
catalog of possible checklist items from publications
in these other domains. Some items thus identified
were clearly not relevant to original articles in JCBFM,
and after exclusion of these, we selected 15 main items and
9 supplementary items which, in our view, captured most
of the important aspects of study reporting, which might
reasonably be expected from publications in JCBFM (see
Table 1).
Assessment Process
For all items apart from the reporting of specific test
statistics (question 8) and the appropriateness of the
statistical tests used (question 8a), two nonblinded
reviewers (KE and HV) independently extracted data for
publication quality by reading each original article and
then reporting whether the specific checklist item was met
by the publication (yes), not met by the publication (no),
not applicable to that publication (n.a.), or unknown.
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An independent, blinded expert reviewer (PS) assessed for
the presence of specific test statistics (item 8) and whether
the analytical test statistics were appropriate for the
underlying experimental design (item 8a). In a statistical
analysis, the method of choice depends on the type of data,
e.g., numerical or categorical, as well as on the structure
and distribution of data. Thus, it was investigated whether
the chosen analysis was suitable for data at hand. For
example, for a comparison of three groups with repeated
continuous measurements, it was checked whether an
appropriate method, such as an analysis of variance with
repeated measures was chosen. To do so, statistical details
reported in the selected publications were extracted and
given to the reviewer alongside the publications. Moreover,
the order in which publications were presented was
randomized and the reviewer was blinded to authors,
institution, journal, volume number, and digital object
identifier number of the publications.
Interobserver Agreement
k-Statistics, representing the extent of agreement between
the two scorers, were calculated for each item, except
for 8a. As k is highly affected by the prevalence of t-
positive scores, we also calculated separate indices of the
proportionate agreement in the observers’ positive (‘yes’)
and negative (‘no’) decisions (Feinstein and Cicchetti,
1990; Cicchetti and Feinstein, 1990).
Results
A total of 193 original scientific articles were published in
JCBFM in the year 2008. Of these, 95 (49%) described
animal studies, 49 (25%) described in vitro experiments,
34 (18%) included human participants, 8 (4%) were review
articles, and 29 (15%) were of other types. Of the 193 total
publications, 156 were original studies. Quality assessment
of these studies was performed using the checklist
presented in Table 1. The proportion of animal, cell
culture, and human studies meeting each of the checklist
items is given in Table 2, and is summarized in Figure 1.
Interobserver Agreement
To ensure appropriate robustness to the assessment, each
item was determined by two investigators blinded to the
assessment of the other. Interobserver agreement is given in
Supplementary Table 1.
Discussion
Systematic assessment of all 156 original articles published
in JCBFM in 2008 revealed a surprisingly high prevalence
of deficiencies in the reporting of key components of
scientific quality: design, reporting, and statistics. This is
the first systematic study of this type in research on
physiology and pathophysiology of brain metabolism and
blood flow, but several studies and commentaries have
already hinted that methodological and reporting problems
are prevalent, and that this might be an important
contributor to the ‘translational roadblock’ that exists in
the field (Dirnagl, 2006; Sena et al, 2007; Phillips et al,
2008; Fisher et al, 2009; Crossley et al, 2008; Jerndal et al,
2010; Dirnagl and Macleod, 2009). Other investigators have
found similar disappointing quality indicators when
surveying publication practice of animal experiments in
general (Kilkenny et al, 2009), medical research in general
(Altman, 2002), and statistics in experimental and clinical
medical papers (Garcı ´a-Berthou and Alcaraz, 2004; Wil-
liams et al, 1997; Holmes, 2004; Zinsmeister and Connor,
2008; Phillips et al, 2008; Hoffmann, 1984; Glantz, 1980).
Scientific publications are the main source of informa-
tion in research. Original publications need ‘to convey to
the reader relevant information concerning the design,
conduct, analysis, and generalization of the trial. This
information should provide the reader with the ability to
make informed judgments regarding the internal and
external validity of the trial. Accurate and complete
reporting also benefits editors and reviewers in their
deliberations regarding submitted manuscripts.’ (Begg
et al, 1996). Ethical considerations regarding the use of
animals in research and the well-being of patients dictate
Table 1 Questionnaire used to assess the quality of publications
Category Question
Design
1 Was a primary/research hypothesis stated?
1a Was an aim/purpose of study stated?
2 Was the design randomized? (Dirnagl, 2006)
3 Was allocation concealed?
4 Was outcome assessed blinded?
5 Was a statement about sample size given? (e.g., a priori
power analysis) (Altman, 2002)
6 Was study design stated? (Andersen, 1990)
7 Were inclusion and exclusion criteria stated? (Altman
et al, 1983; Andersen, 1990)
Analysis and statistics
8 Were specific test statistics reported? (Altman, 2002)
8a Were statistical tests appropriate for study design?
9 Was a measure of variance reported? (Andersen, 1990)
9a Were s.d. reported?
9b Were s.e.m. reported?
9c Were confidence intervals reported?
10 Were the units of analysis specified? (Andersen, 1990;
Altman, 2002)
10a Were individual data points reported (e.g., plot)?
10b Were raw data given?
Reporting
11 Were numerical values only given in graphs? (regarding
primary hypothesis/main experiment) (Altman, 1998)
12 Was mortality/number of dead quantified and stated?
(Andersen, 1990)
13 Was the source of experimental organism/cells given?
(species, strain, etc.)
13a Was the laboratory/company stated where experimental
organism was acquired from?
13b Was the age of the experimental organism given?
13c Was the weight of the experimental organism stated?
14 Was a control group reported? (Andersen, 1990)
15 Was a conflict of interest statement given?
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good laboratory or clinical practice (GLP, GCP), and that
reporting of the results be comprehensive, accurate, and
transparent. More than a decade ago, following an analysis
of deficiencies in the quality and reporting of randomized
clinical trials, journal editors, epidemiologists, and statis-
ticians have published the CONSORT statement and the
CONSORT checklist of items to include when reporting a
randomized trial (Moher et al, 2001a). Since then, the
quality of reporting and quality in general of randomized
clinical trials has greatly improved, which has at least in
part been attributed to this process (Plint et al, 2006;
Hopewell et al, 2010). The current study was conducted to
further raise the awareness of quality issues in neuroscience
research, and to further the implementation of a CONSORT-
like statement in experimental medical research.
Specific Checklist Items
Hypothesis/Purpose: A clear statement on the objective of
the study or its main hypothesis being tested is critical for
the reader to assess the appropriateness of the study
design, methods, analysis, and implications. Surprisingly,
only 30% of publications explicitly stated a primary
research hypothesis; however, 97% indicated the aim or
purpose; 44% indicated both, and only 3% gave neither a
hypothesis nor an aim (percentages given herein and below
represent the mean of both reviewers).
Interestingly, clinical studies involving human partici-
pants, wherein the regulatory environment is more strict,
were only slightly better than experimental laboratory or
in vitro studies (see Figure 1, Table 2). Where a study
hypothesis is well defined and an analysis protocol agreed
in advance of experiments being conducted, then the risk
of chance associations being considered of significance are
diminished; this is the laboratory equivalent of the post
hoc subgroup analysis of clinical trial data, which can
at best be considered hypothesis generating only. Where a
clear hypothesis is stated, data presented that are
not relevant to this can be interpreted appropriately
(Andersen, 1990).
Randomization/Allocation Concealment/Blinded Assess-
ment of Outcomes: Randomization, allocation concealment,
and blinded assessment of outcomes are the key measures
to reduce bias and to improve the internal validity of a
study. Nevertheless, <20% of the relevant publications
Table 2 The total number of animal, in vitro, and human studies meeting each of the checklist items (yes, not applicable (n.a.), and
unknown (U)) as assessed by both reviewers in relevant publications (those which were not n.a.) (summarized in Figure 1)
Category Question Animal (n=190) In vitro (n=98) Human (n=68) Overall (n=312)
Yes n.a. U Yes n.a. U Yes n.a. U Yes n.a. U
Design
1 Primary/research hypothesis stated? 51 (27) — — 32 (33) — — 24 (35) — — 93 (30) — —
1a Aim/purpose of study stated? 181 (95) — — 90 (92) — — 67 (99) — — 300 (96) — —
2 Randomization? 39 (22) 13 (7) — 14 (15) 3 (3) — 5 (8) 6 (9) — 46 (15) 20 (6) —
3 Allocation concealment? 14 (8) 6 (3) — 2 (2) 3 (3) — 3 (5) 3 (4) — 17 (6) 10 (3) —
4 Blinded assessment of outcome? 28 (15) — — 13 (13) — — 17 (25) — — 46 (15) — —
5 Statement about sample size given 2 (1) 1 (1) — 2 (2) 1 (1) — 0 (0) — — 2 (1) 1 (0) —
6 Is study design stated? 6 (3) — — 2 (2) — — 9 (13) — — 16 (5) — —
7 Are inclusion and exclusion criteria
stated?
26 (14) — — 11 (11) — — 29 (43) — — 58 (19) — —
Analysis and statistics
8 Are specific test statistics reported? 84 (88) — — 36 (73) — — 31 (91) — — 132 (85) — —
8a Are applied statistical tests appropriate
for study design?
73 (77) — — 42 (88) 1 (2) — 30 (88) — — 127 (81) — —
9 Measure of variance reported? 183 (97) 2 (1) — 95 (99) 2 (2) — 66 (99) 1 (1) 3 (4) 302 (97) 2 (1) —
9a s.d. reported? 86 (47) 8 (4) — 36 (38) 2 (2) 14 (15) 44 (66) 1 (1) 3 (4) 150 (50) 9 (3) 25 (8)
9b s.e.m. reported? 92 (51) 8 (4) — 47 (49) 2 (2) 14 (15) 24 (36) 1 (1) 3 (4) 140 (46) 9 (3) 25 (8)
9c Confidence interval (CI) reported? 5 (3) 8 (4) — 1 (1) 2 (2) 14 (15) 5 (7) — — 10 (3) 9 (3) 25 (8)
10 Units of analysis given? 85 (34) 1 (1) — 37 (38) 1 (1) — 40 (62) 3 (4) — 140 (46) 5 (2) —
10a Are individual data points reported 24 (13) — — 16 (16) — — 22 (32) — — 59 (19) — —
10b Are raw data given? 13 (7) — — 11 (11) — — 13 (19) — — 34 (11) — —
Reporting
11 Numerical values only given in graphs? 110 (59) 2 (1) — 50 (52) 2 (2) — 28 (41) — — 163 (53) 2 (1) —
12 Mortality/number of dead stated? 16 (9) 19 (10) — 6 (8) 24 (24) — 4 (8) 19 (28) — 22 (8) 53 (17) —
13 Source of experimental organism/cells
given?
158 (92) 19 (10) — 82 (93) 10 (10) — 23 (100) 45 (66) — 224 (93) 71 (23) —
13a Laboratory/company stated where
experimental organism was acquired
from?
91 (53) 19 (10) — 51 (57) 9 (9) — 13 (54) 44 (65) — 133 (55) 68 (22) —
13b Age of experimental organism given? 75 (42) 11 (6) — 38 (46) 16 (16) — 50 (77) 3 (4) — 145 (50) 23 (7) —
13c Weight of experimental organism stated? 108 (60) 11 (6) — 38 (46) 16 (16) — 19 (29) 3 (4) — 149 (52) 23 (7) —
14 Is a control group reported? 162 (86) 1 (1) — 80 (82) 1 (1) — 49 (73) 1 (1) — 254 (82) 3 (1) —
15 Conflict of interest statement given? 54 (28) — — 23 (23) — — 31 (46) — — 94 (30) — —
Some publications reported more than one type of subject (animal, in vitro, and human) and are therefore represented more than once. Values in brackets
represent percentages. Only one reviewer assessed questions 8 and 8a, and therefore, values are for half the sample size given in column headings.
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assessment of outcomes. In the few studies in which
randomization was mentioned, it was unclear whether
proper procedures were followed. We cannot exclude the
possibility that some studies may have used such measures
but did not report these. Moreover, in some studies,
randomization or blinded assessment may not have been
feasible, or indicated. However, as reporting of these
items is not common, it is often not possible for readers
to assess whether such studies are indeed flawed. It
should be noted that in two recent studies focusing on
experimental stroke studies, roughly 50% of the included
studies reported randomization (Minnerup et al, 2010;
Philip et al, 2009).
Figure 1 Comparison of the results obtained by two reviewers (HV: solid color; KE: diagonal stripes) assessing the publications
presenting all included publications (N=156, yellow), animal studies (N=95, blue), in vitro studies (N=49, green), and those
involving human participation (N=34, red). x axis values indicate the corresponding question number as it appeared on the
questionnaire (see Table 1), and y axis values represent the number of publications expressed in percentages (0% to 100%). For
numerical values, see Table 2.
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sample size calculations or power analyses, or the effect
size that could have been detected, given the variance of
data and the preset levels for a (risk of committing a type I
error, or false positive) and b (risk of committing a type II
error, or false negative) (Sterne et al, 2001; Mulaik et al,
1997; Schlattmann and Dirnagl, 2010a). The statistical
power of a study informs us not only about the risk of false
negatives but it is also directly related to the reproduci-
bility and positive-predictive value of the experimental
results (Ioannidis, 2005). Again, in some of the studies in
this survey, a priori sample size calculations would not
have made sense. However, in the overwhelming number
of studies, they would clearly have been helpful in
designing experiments. Most studies included here were
in fact grossly underpowered; with sample sizes of 10 per
group (which is at the high end of sample sizes found), an
a-value of 0.05 and a b-value of 0.8, effect sizes of 1.33
times the s.d. can be detected (two-sided, independent
samples t-test). As variance in most of the reported
experiments is quite high (e.g., s.d. 30% of the mean), this
implies that these studies are only powered reliably to
detect a 32% mean change in outcomes, such as infarct
volume or neurobehavioral score.
Study Design: In this sample of publications, assessing
and categorizing study design was very difficult. In our
view, this was not so much to do with problems in
individual manuscripts but rather to do with the lack of a
well-established vocabulary to describe study design in
experimental life sciences. This contrasts with the well-
established nomenclature for clinical studies, in which
categories such as randomized-controlled trial, cohort
study, diagnostic trial, screening trial, phase I to IV trial,
etc., help to quickly understand the design and assess
the implications of a study. We propose to introduce an
analogous terminology to the field of experimental medi-
cine, such as phase I experimental trial (safety, tolerability,
pharmacokinetics, pharmacodynamics, dose finding; not
necessarily in a disease model; small group sizes), phase II
experimental trial (dosing and safety in disease model,
efficacy, proof of concept), and phase III experimental trial
(efficacy, larger group sizes, confounders). If applicable,
experimental trial types should be further specified as
‘randomized’ and ‘controlled’, if applicable.
Inclusion and Exclusion Criteria/Mortality/Control
Group: Reporting inclusion and exclusion criteria in the
‘Methods’ section, and exclusions, dropouts, or mortality
(including the reasons behind it) of the experimental
groups in the ‘Results’ section is another key element to
prevent bias and to improve the internal validity of a study.
We found that <20% (29/156) of the publications reported
inclusion and exclusion criteria.
Mortality was reported in only 8% (20/129) of studies in
which it was relevant; a further 27 studies reported for
instance imaging findings, human participants, or purely
in vitro experiments. We propose that it should be made
mandatory to publish mortality rates in animal experi-
ments, as this would prevent the masking of a severe bias
which could, e.g., result from excluding severely affected
animals in only one of the experimental groups. Control
groups are crucial measures to safeguard that an effect is a
true effect of the manipulation or condition under study,
and to minimize the effect of other, unintended variables
on the results. More than 80% of the publications reported
the use of control groups. Assuming that in a fraction of
articles, control groups would not have made sense, this
figure is comforting as it points to a widespread use of this
key element of the scientific method.
Experimental Animals and Study Subjects: To under-
stand the implications of a study, and potentially to be able
to reproduce experiments, we need to be well informed
about the specific characteristics of the experimental
animal species, strain, and substrain, supplier, genetic
background, age, weight, and sex, among others, which
must be considered critical information for reviewers and
readers alike.
General Reporting of Statistical Analysis: Specific test
statistics were reported in 85% of the assessed publica-
tions. Of those, expert statistical assessment revealed that
81% (127/156 relevant publications) of the cases used
appropriate approaches and test. The remaining articles
either used inappropriate statistical analyses or did not
supply the reader with sufficient information to compre-
hend the reported results. The lack of information made it
difficult to evaluate the appropriateness of given statistical
tests, and moreover, of the 156 assessed studies, 3 did not
provide enough information to judge the methodological
quality.
When performing statistical analysis, the method
of choice depends on the type of data, e.g., numerical or
categorical, as well as on the structure and distribution
of data. In all studies assessed, the choice of statistical
method was appropriate for the type of data under study.
However, in terms of structure, the results were different.
Among others factors, the structure of the data is given by
the number of groups considered, e.g., one, two, or more
than two groups. If the number of groups is larger than two,
applying multiple t-tests without correcting for multiple
comparisons is not appropriate. This error occurred in 4 of
the 156 studies reviewed.
Often, a more complex design is chosen, e.g., when
several measurements per animal or subject are taken.
In this case, the data points are dependent as we are
measuring on the same subject. This introduces a correla-
tion between individual measurements. In such cases,
statistical tests that require independent data, such as the
unpaired t-test or an analysis of variance, are not appro-
priate. This error occurred in 22 of the 156 assessed
studies. As part of a series on statistics in cerebrovascular
research, JCBFM presents methods that are appropriate for
dependent data (Schlattmann and Dirnagl, 2010a,b).
Measure of Variance: A high number of publications
include a measure of variance. More than 90% (151/155) of
the relevant included publications provide the assessor
with s.e.m. (46%), s.d. (49%), or confidence interval (4%).
A further 9% of relevant publications did not state the
type of variance reported. Although popular because it
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purposes, s.e.m. is not an acceptable measure. The latter
is an estimate for the precision of estimating the mean, not
a description of the sample (Altman and Bland, 2005;
Schlattmann and Dirnagl, 2010a).
Units of Analysis/Data Points: Most of the assessed
studies represent data numerically, and more or less
directly indicate the unit of analysis (e.g., an Eppendorf
tube, right or left hemisphere, a single animal, a group or a
cage of animals). Nonetheless, in some cases, the experi-
mental unit/unit of analysis could not be identified.
Data for individual study objects (instead of only
presenting group data) were found in 30 publications,
and raw data were provided in 17 publications. Reporting
raw data and individual data points can help the reader to
assess the quality and dispersion of results. As most
studies were reporting on rather low numbers of subjects,
and because most journals allow almost unlimited pub-
lication of additional data as Supplementary material on
the website of the journal, we strongly encourage authors to
provide as much detailed information as useful and
possible. This, in many cases, includes the plotting
of individual data points in scatter plots and the listing
of numerical values in tables (Schlattmann and Dirnagl,
2010a).
Limitations of this Study: Our survey has a number of
limitations. None of the dichotomized percentages (yes/no)
of the items of our questionnaire (Table 1) can be inter-
preted as quality statements in themselves. For example, if
it is said that 85% of all studies did not use allocation
concealment, then it must be kept in mind that not all
studies may have allowed designs in which allocation
could be concealed, or allocation concealment may have
not made sense. We have repeatedly alluded to this
constraint in the above discussion. In any case, these
numbers present a first overview on the reporting and
statistics practices of the surveyed volume.
Our approach was to define criteria and then apply them
to all publication categories (such as experimental, animal,
and clinical) rather than to define criteria specific to each.
Although there might be concerns that not all criteria
would be appropriate in each publication category, in fact
this was not the case; each criterion was scored as being
present in at least one publication from each category and
at worse, one-third of publications in a category could be
scored (source of experimental organism, human studies).
Even with criteria specific to each publication category, we
would have some in which criteria were not appropriate,
and we believe that our approach has the benefit of being
simple and broadly applicable.
It might be argued that some of the questions used in this
survey may not be answered in an unambiguous manner.
For example, we might have answered question 1: Primary/
research hypothesis stated? with ‘no’, because the hypoth-
esis was not explicitly phrased as such (‘In our study we
tested the hypothesis that.’), but the author of the study
might object because he might insist that the hypothesis
reveals itself allusively from the text. However, we argue
that a suitably skilled reader should be clearly presented
with all the relevant information of a scientific commu-
nication, which includes aims, purpose, and hypotheses,
to be able to understand, analyze, and potentially replicate
the findings.
To assess potential bias of the assessor, we used two
assessors, and found a very high degree of interrater
agreement. In all categories, questions were more often
answered by the scorers with ‘no’ than with ‘yes’. For many
questions, a score of ‘yes’ was low. This in some instances
lead to low k-values despite high agreement between
scorers (Supplementary Table 1), as k is not reliable for rare
observations because it is affected by the prevalence of
observations.
Restricting our analysis to JCBFM may introduce bias,
which precludes generalization of our results to studies
published in other journals. This is very unlikely,
as JCBFM is one of the top-ranked journals in the field of
experimental cerebrovascular and stroke research. Stan-
dards for publication, authors, reviewers, etc., are similar
to other journals in the field, such as Stroke. We have opted
to restrict our analysis to this journal, as its scope was
ideally suited to survey experimental studies and clinical
proof-of-concept studies. We hypothesize that surveying
related journals, and even scientific journals in other
experimental-translational areas in life sciences would
yield very similar results.
Conclusions
In this systematic survey, we found indicators for defi-
ciencies in the design, reporting, and statistical analysis of
the original articles in a recent volume of JCBFM, one
of the leading journals in the cerebrovascular field. There
is ample indirect and direct evidence that this is not a
problem unique to this particular journal, or even research
field. We, along with others (e.g., Fisher et al, 2009;
Macleod et al, 2009), believe that quality issues in
experimental life sciences are an important reason why
we are currently facing roadblocks to translation from
bench to bedside (and vice versa). Only a joint effort of the
scientific community (authors, readers, reviewers, editors,
professional societies, etc.) can improve the current
situation. The results of our study, together with a thorough
analysis of the measures that were successfully taken in
clinical medicine to improve study quality, indicate some
of the action points.
We propose that, in analogy to the CONSORT statement,
a set of standards for reporting of experimental studies in
biomedicine is used. Like with CONSORT, journal editors
need to adopt these standards. Journals need to educate
their readers and create awareness in areas, such as proper
study design and analysis. Indeed, Kilkenny et al (2010)
have recently proposed such reporting guidelines (Animal
Research Reporting In Vivo Experiments, ARRIVE; http://
www.nc3rs.org/ARRIVE) using the CONSORTstatement as
a foundation. Reviewers need to be more critical regarding
missing hypotheses, deficiencies of experimental design,
insufficient statistical power, or inadequate information in
the submitted articles. Most importantly, the upcoming
generation of scientists, the students, need to be trained in
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etc. It has been pointed out that experimental biomedicine
should not be constrained by rules and regulations. More
specifically, some scientists argue that hypotheses, power
calculations, or a priori defining the design of a study or its
analysis might suffocate the ingenuity of the experimen-
talist. Quite to the contrary: scientific brilliance or
serendipity are traits of the investigator that are unrelated
to the standards of scientific publishing. Even the most
ingenious finding must be supported by solid and
reproducible experiments, which are communicated in a
comprehensible manner.
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